skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Concurrent Chagas’ disease and borderline disseminated cutaneous leishmaniasis: The role of amiodarone as an antitrypanosomatidae drug

Case report

(2205) Views  (485) Full article downloads

Authors: Alberto E Paniz-Mondolfi, Alexandra M Pérez-Álvarez, Oscar Reyes-Jaimes, Gustavo Socorro, Olga Zerpa, et al

Published Date June 2008 Volume 2008:4(3) Pages 659 - 663
DOI: http://dx.doi.org/10.2147/TCRM.S2801

Alberto E Paniz-Mondolfi1,4, Alexandra M Pérez-Álvarez1, Oscar Reyes-Jaimes2, Gustavo Socorro1, Olga Zerpa3, Denisa Slova4, Juan L Concepción5

1Laboratorio de Estudio de Antígenos, Instituto de Biomedicina, “Hospital José Gregório Hernández”, Instituto Venezolano de los Seguros Sociales, Caracas, Venezuela; 2Departamento de Dermopatología, Instituto de Biomedicina, 3Sección de Leishmaniasis, Instituto de Biomedicina, Caracas, Venezuela; 4Department of Pathology and Laboratory Medicine, St. Luke’s – Roosevelt - Beth Israel Medical Center, University Hospital of Columbia University College of Physicians and Surgeons, New York, USA; 5Laboratorio de Enzimología de Parásitos, Facultad de Ciencias, Universidad de Los Andes, Mérida, Venezuela

Abstract: The occurrence of mixed infections of Trypanosoma cruzi and Leishmania spp. is becoming a common feature in Central and South America due to overlapping endemic areas. Unfortunately, the possibilities for treating flagellated kinetoplastid infections are still very limited and most of the available drugs exhibit severe side effects. Although the development of new drugs for Leishmania has markedly improved in the last years, the tendency is still to employ antimonial compounds. On the other hand, treatment for Chagas’ disease is only available for the acute phase with no effective therapeutical options for chronic stage disease. The following case report substantiates the recently discovered effect of amiodarone as a nonconventional antiparasitic drug, particularly against Leishmania, breaching a new perspective in the therapeutic management of these important infectious parasitic diseases.

Keywords: Chagas’ disease, leishmaniasis, chemotherapy, amiodarone








Readers of this article also read:

Cost-effectiveness analysis of electrochemotherapy with the Cliniporator™ vs other methods for the control and treatment of cutaneous and subcutaneous tumors
Towards a new standard of perioperative fluid management
Moderate and severe plaque psoriasis: cost-of-illness study in Italy
Nonlinear analysis of the heartbeats in public patient ECGs using an automated PD2i algorithm for risk stratification of arrhythmic death
Efficacy of deoxyspergualine for antibody-mediated rejection and proteinuria after kidney transplantation
An “acquired” hemoglobin J variant in a sickle cell disease patient
Current and emerging therapeutic options for the treatment of chronic chagasic cardiomyopathy
Current and developing therapeutic agents in the treatment of Chagas disease
The effect of reminder systems on patients' adherence to treatment
The impact of pharmacist face-to-face counseling to improve medication adherence among patients initiating statin therapy